Page last updated: 2024-09-04

tariquidar and Local Neoplasm Recurrence

tariquidar has been researched along with Local Neoplasm Recurrence in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blumenschein, G; Boniface, G; Booser, D; Fleming, DR; Hortobagyi, GN; Ibrahim, N; Pusztai, L; Rivera, E; Rouzier, R; Symmans, FW; Theriault, R; Wagner, P; Wong, F	1

Trials

1 trial(s) available for tariquidar and Local Neoplasm Recurrence

Article	Year
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 2005, Aug-15, Volume: 104, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Quinolines; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed	2005

Article

Year

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.

Cancer, 2005, Aug-15, Volume: 104, Issue:4

Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Quinolines; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed

2005